InSilico Medicine (03696.HK) and Bora Pharmaceuticals Announce Strategic Alliance with Potential Value Exceeding US$2.5 Billion

NewTimeSpace News: InSilico Medicine Cayman TopCo (03696.HK) announced on July 15 in a voluntary announcement that InSilico Medicine and Bora Pharmaceuticals Co., Ltd. (Bora; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, have announced a multi-faceted strategic alliance (the Alliance). The Alliance will lay the foundation for a broad, multi-faceted cooperation framework, with specific cooperation details subject to further discussion and the execution of definitive agreements between the parties. If fully implemented, the potential value of the proposed collaboration is expected to exceed US$2.5 billion.

The proposed collaboration under the Alliance will be agreed upon by InSilico Medicine and Bora through subsequent negotiation and execution of definitive agreements. It aims to integrate InSilico Medicine's proprietary Pharma.AI platform's technological advantages in target discovery, generative chemistry and molecular optimization, with Bora's professional capabilities in global drug development, manufacturing, quality management and commercialization. By connecting AI-empowered R&D systems with automation-driven development, manufacturing and quality execution processes, InSilico Medicine and Bora aim to jointly create a new generation of drug innovation models, bridging the capabilities required for the design and development, manufacturing and delivery of novel molecules to patients with unmet medical needs.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.